Cancer Management and Research (Feb 2020)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience

  • Guo Q,
  • Chen M,
  • Xu H,
  • Lu T,
  • Zhou H,
  • Chen Y,
  • Zong J,
  • Xu Y,
  • Chen B,
  • Wang B,
  • Zhu L,
  • Pan J,
  • Lin S

Journal volume & issue
Vol. Volume 12
pp. 1387 – 1396

Abstract

Read online

Qiaojuan Guo, 1–3,* Mengwei Chen, 4,* Hanchuan Xu, 1 Tianzhu Lu, 1 Han Zhou, 1 Yanyan Chen, 1 Jingfeng Zong, 1 Yun Xu, 1 Bijuan Chen, 1 Bingyi Wang, 1 Lili Zhu, 1 Jianji Pan, 1, 2 Shaojun Lin 1, 2 1Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People’s Republic of China; 2Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, People’s Republic of China; 3Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 4Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China*These authors contributed equally to this workCorrespondence: Shaojun LinDepartment of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420 Fuma Road, Fuzhou 350014, People’s Republic of ChinaTel +86 591-83638732Fax +86 591-83928767Email [email protected]: In this study, we retrospectively evaluated a series of metastatic nasopharyngeal carcinoma (mNPC) patients who received oral maintenance chemotherapy using S-1/capecitabine after systemic chemotherapy and local radiation therapy, and aimed to explore potential efficient treatment strategies for this subset of patients.Patients and Methods: Thirty-seven patients with mNPC (19 newly diagnosed metastatic patients and 18 metastatic cases after definitive chemoradiotherapy) who received the treatment strategies mentioned above were analyzed.Results: After a median follow-up time of 37 months, the 3-year progression-free survival and overall survival (OS) rates were 47.6% and 87.7%, respectively. The median time to progression was 27.6 months, while the median OS was not reached at time of last follow-up. The most common acute adverse events were hematological and gastrointestinal toxicity, and all were tolerable and curable.Conclusion: Oral maintenance chemotherapy using S-1/capecitabine in mNPC patients after systemic chemotherapy could yield a superb outcome. Further multicenter prospective clinical trials are warranted.Keywords: metastatic nasopharyngeal carcinoma, maintenance chemotherapy, systemic chemotherapy, S-1, capecitabine

Keywords